First Ph.D. Candidates Selected for Johns Hopkins-MedImmune Scholars Program
Last year, Johns Hopkins University and MedImmune announced their collaboration on a unique new initiative, the Johns Hopkins-MedImmune Scholars Program. The program has just selected its first Ph.D. candidates for a curriculum that will prepare them for careers in the biopharma industry.
Inez Lam and Natalia Majewska, both first-year Johns Hopkins University Ph.D. students, will participate in the five-year program, the first-of-its-kind in the United States, to gain a better understanding of the process and challenges of drug discovery and development. Upon completion, they will receive a traditional Ph.D. from The Johns Hopkins University.
“Having the combined resources of MedImmune and Johns Hopkins, a large network of people who can help guide me as well as access to more equipment will allow me to have a more wholesome Ph.D.,” says Majewska, who is studying chemical engineering at the Whiting School of Engineering.
Over the next few years, Majewska will focus her research on developing a better Chinese hamster ovary cell production platform. Chinese hamster ovary cells, often referred by the shorthand CHO cells, are used by research and commercial institutions for the production of therapeutic proteins. Because Majewska will work on a proprietary cell line, she anticipates that she will spend most of her time at MedImmune’s Gaithersburg, Maryland campus but will have weekly meetings with her Johns Hopkins advisor, Michael Betenbaugh.
“This is an opportunity for someone like me to delve into a problem that they’ve been thinking about but haven’t had the time or resources to do,” says Majewska, who aims to go into the biopharma industry once she completes the program and is considering doing so with a business focus.
Lam, a biomedical engineering Ph.D. student in the Institute for Computational Medicine, will focus on building computational models to better understand how drugs work in the body. Lam is currently working with her Johns Hopkins advisor, Feilim Mac Gabhann, and MedImmune to determine where their scientific interests overlap in order to identify precisely the focus of her thesis. Still, Lam believes that this arrangement will further biological understanding, improve therapies and treatments and, ultimately, produce better patient outcomes.
“Industry is known for having large amounts of data, and they often don’t have the time or investment to make full use of it. In academia, we have more flexibility to look into that data,” Lam says. “I think this program will play to each of our strengths, making the best of all our resources.”
According to Peter Espenshade, associate dean for graduate biomedical education at the Johns Hopkins University School of Medicine, the Johns Hopkins-MedImmune Scholars Program will facilitate more opportunities for students as they can focus on building a career in academia or in industry.
“People are starting to realize that they need to think earlier about what they want to do and what aligns with their skills and personalities,” Espenshade says.
With Ph.D. students shifting their career paths, Espenshade says the question becomes: Are we training them only for careers in academia? The Johns Hopkins-MedImmune Scholars program, like the Cambridge-AstraZeneca PhD Programme in Chemical Synthesis developed in 2015, enables students to gain exposure to a variety of career paths within industry.
Determining the success of the program will take years, Espenshade says, and will be based on the careers of the Ph.D. students, collaborative publications and the resulting research. For now, Lam and Majewska are pioneers and are relishing the opportunity they have.
“I think this program could be the foundation on which future programs are based,” Lam says. “Natalia and I have the honor of paving the way. How we go through the program will help set an example for other students and similar programs that will be modeled after this. I’m grateful for this opportunity.”